Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Significance: The hypoxic microenvironment in solid tumors is known to reduce the efficacy of anticancer treatments in many cancer types, including breast cancer. This study shows hypoxia induces an amino acid transporter, SNAT2, which then causes resistance to antihormone therapy. We show major interplay between genes induced by estrogen receptor and hypoxia. Hypoxia-inducible factor 1α compensates for the loss of expression of estrogen receptor-α (ERα) for maintaining SNAT2 expression under hypoxia or endocrine therapies. SNAT2 overexpression produces complete resistance to antiestrogen therapy in vivo and is induced in tamoxifen resistance, and its expression is associated with poor survival in breast cancer and resistance to endocrine therapy in ERα + luminal B patients. Our findings thus have revealed a previously unidentified mechanism for antiestrogen resistance driven by tumor metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6. SNAT2 expression is related to poor outcomes in endocrine-treated breast cancer patients. (A) Xenograft growth curves of MCF7 parental and SNAT2-o clones ± bevacizumab (BEV) or ± fulvestrant (FULV) treatment. CTL, control. ***P < 0.001, **P < 0.01, *P < 0.05; linear regression followed by Student’s t test (n = 5). (B) Kaplan–Meier plot for patients from the TGCA breast cancer invasive cohort (ALL and ER+ cohorts) stratified according to the expression of SNAT2 mRNA expression (T1, lower tertile; T2, middle tertile; T3, upper tertile). Overall survival (OS) was evaluated. The graph shows that high tumor SNAT2 levels are associated with increased patient mortality. Subanalysis based on tertile expression showed that the higher SNAT2 mRNA expression (upper tertile) cohort has a lower survival compared with the lower tertile cohort (T3 vs. T1). HR, hazard ratio. (C) Kaplan–Meier plots for luminal A and B ER+ breast cancer patients (Left) and for same subgroups that received endocrine [aromatase inhibitor (AI) or tamoxifen (TAM), Center] or tamoxifen only (Right). Patients were stratified according to the expression of SNAT2 mRNA [above (red) versus below (black) third quartile]. Recurrence-free survival was evaluated.](https://figures.cochat.ai/paper-figures/4f913bb6ca604c7dad67dd935041e2a5/hypoxia-induced-switch-in-snat2-slc38a2-regulation-generates-endocrine-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition to promoting lipid synthesis, the HIFs also directly promote lipid uptake and lipid droplet formation, while decreasing β-oxidation (see section on mitochondria), which increases the cellular fatty acid pool that can be utilized as an energy source or channeled to other uses to facilitate tumor proliferation.”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredIn the citing paper
“Hypoxic conditions promote the uptake of glutamine by increasing the levels of glutamine transporters such as SLC1A5, the SLC1A5 variant, and SLC38A216,65”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Hypoxia is a key microenvironmental difference between tumor and normal tissues and is related to poor clinical prognosis and resistance to therapies in many solid tumors, including breast cancer (6).”
Self-citationHypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Harbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001 · cited 1×
“Although SNAT2 is induced by the UPR (56) and Myc was found to selectively bind to the promoter regions of SNAT2 (57), we did not find any correlation between c-Myc copy number and SNAT2 mRNA levels in breast cancer patients.”
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
An oestrogen-receptor-α-bound human chromatin interactome
Fullwood, M. J., Liu, M. H., Pan, Y. F., Liu, J., Xu, H., Mohamed, Y. B., Orlov, Y. L., Velkov, S., Ho, A., Mei, P. H., et al. (2009) · Nature · doi:10.1038/nature08497 · Cited by 1,721
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,717
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683 · cited 1×
“ER breast cancer cell lines are known to be more susceptible to serine depletion, probably due to lack of amplification of phosphoglycerate dehydrogenase, and thus are less addicted to serine metabolism compared with ER tumors (49, 50).”
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. J., Heffron, G., Metallo, C. M., Muranen, T., Sharfi, H., et al. (2011) · Nature Genetics · doi:10.1038/ng.890 · Cited by 1,120 · cited 1×
“ER breast cancer cell lines are known to be more susceptible to serine depletion, probably due to lack of amplification of phosphoglycerate dehydrogenase, and thus are less addicted to serine metabolism compared with ER tumors (49, 50).”
Self-citationSzász, A. M., Lánczky, A., Nagy, Á., Förster, S., Hark, K., Green, J. E., Boussioutas, A., Busuttil, R., Szabó, A., & Győrffy, B. (2016) · Oncotarget · doi:10.18632/oncotarget.10337 · Cited by 988
Quantitative Analysis of Histological Staining and Fluorescence Using ImageJ
Jensen, E. C. (2013) · The Anatomical Record · doi:10.1002/ar.22641 · Cited by 941
How cancer metabolism is tuned for proliferation and vulnerable to disruption
Schulze, A., & Harris, A. L. (2012) · Nature · doi:10.1038/nature11706 · Cited by 929
Self-citationHolmquist-Mengelbier, L., Fredlund, E., Löfstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, Å., Gradin, K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.026 · Cited by 735
Sansone, P., Savini, C., Kurelac, I., Chang, Q., Amato, L. B., Strillacci, A., Stepanova, A., Iommarini, L., Mastroleo, C., Daly, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704862114 · Cited by 728
High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq
Schödel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C. W., Ratcliffe, P. J., & Mole, D. R. (2011) · Blood · doi:10.1182/blood-2010-10-314427 · Cited by 724 · cited 2×
“HIF-1α and HIF-2α share common targets, including VEGFA, glucose transporter 1 (GLUT1), and erythropoietin (40).”
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · cited 1×
“Of interest, SNAT2 was also strongly up-regulated by hypoxia in ER breast cancer cells; thus, its role in triple-negative breast cancer, which is generally more hypoxic and glutamine-dependent (47), deserves further evaluation.”
Buffa, F. M., Harris, A. L., West, C. M., & Miller, C. J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605450 · Cited by 556
Self-citationKnowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.043 · Cited by 505
Bhutia, Y. D., Babu, E., Ramachandran, S., & Ganapathy, V. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3745 · Cited by 481
Ferrer, C. M., Lynch, T. P., Sodi, V. L., Falcone, J. N., Schwab, L. P., Peacock, D. L., Vocadlo, D. J., Seagroves, T. N., & Reginato, M. J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.026 · Cited by 442
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C., & Piccart, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 435
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219555110 · Cited by 413
Sun, R. C., & Denko, N. C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.022 · Cited by 344 · cited 1×
“There is also up-regulation of glutamine metabolism to support proliferation, lipid biosynthesis, and protection from free radical stress (13).”
Liao, D. J., & Dickson, R. B. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070143 · Cited by 343
Li, J.-L., Sainson, R. C. A., Shi, W., Leek, R., Harrington, L. S., Preusser, M., Biswas, S., Turley, H., Heikamp, E., Hainfellner, J. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0969 · Cited by 299
Self-citationmiRNAs regulate the HIF switch during hypoxia: a novel therapeutic target
Serocki, M., Bartoszewska, S., Janaszak-Jasiecka, A., Ochocka, R. J., Collawn, J. F., & Bartoszewski, R. (2018) · Angiogenesis · doi:10.1007/s10456-018-9600-2 · Cited by 288
Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot
Goberdhan, D. C. I., Wilson, C., & Harris, A. L. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.013 · Cited by 260
Self-citationGenerali, D., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Wigfield, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2690 · Cited by 250
Self-citationKoike, T., Kimura, N., Miyazaki, K., Yabuta, T., Kumamoto, K., Takenoshita, S., Chen, J., Kobayashi, M., Hosokawa, M., Taniguchi, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402088101 · Cited by 245
McIntyre, A., Patiar, S., Wigfield, S., Li, J.-L., Ledaki, I., Turley, H., Leek, R., Snell, C., Gatter, K., Sly, W. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1877 · Cited by 239
Self-citationJeon, Y. J., Khelifa, S., Ratnikov, B., Scott, D. A., Feng, Y., Parisi, F., Ruller, C., Lau, E., Kim, H., Brill, L. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.006 · Cited by 230
The SLC38 family of sodium–amino acid co-transporters
Bröer, S. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1393-y · Cited by 226
HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5
Elorza, A., Soro-Arnáiz, I., Meléndez-Rodríguez, F., Rodríguez-Vaello, V., Marsboom, G., de Cárcer, G., Acosta-Iborra, B., Albacete-Albacete, L., Ordóñez, A., Serrano-Oviedo, L., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.017 · Cited by 205
Inherent DNA‐binding specificities of the HIF‐1α and HIF‐2α transcription factors in chromatin
Smythies, J. A., Sun, M., Masson, N., Salama, R., Simpson, P. D., Murray, E., Neumann, V., Cockman, M. E., Choudhry, H., Ratcliffe, P. J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201846401 · Cited by 195 · cited 1×
“Similarly, a recent systematic analysis of the pangenomic distributions in cancer cells of the two major isoforms of HIF showed strong support for intrinsically distinct patterns of binding, in which disruption of either HIF gene had very little effect on the binding of the other, with little evidence for cross-compen…”
Self-citationMetabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
McIntyre, A., & Harris, A. L. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404271 · Cited by 185
Self-citationSansone, P., Ceccarelli, C., Berishaj, M., Chang, Q., Rajasekhar, V. K., Perna, F., Bowman, R. L., Vidone, M., Daly, L., Nnoli, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10442 · Cited by 176
Robertson, J. F. R., Lindemann, J. P. O., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Emerson, L., Dean, A., & Ellis, M. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2192-4 · Cited by 172
Choudhry, H., Schödel, J., Oikonomopoulos, S., Camps, C., Grampp, S., Harris, A. L., Ratcliffe, P. J., Ragoussis, J., & Mole, D. R. (2014) · EMBO reports · doi:10.1002/embr.201337642 · Cited by 165
Self-citationEndocrine treatment in breast cancer: Cure, resistance and beyond
Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 153
Glutamate enrichment as new diagnostic opportunity in breast cancer
Budczies, J., Pfitzner, B. M., Győrffy, B., Winzer, K., Radke, C., Dietel, M., Fiehn, O., & Denkert, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.29152 · Cited by 142
El Ansari, R., Craze, M. L., Miligy, I., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0946-6 · Cited by 139
Yang, J., AlTahan, A., Jones, D. T., Buffa, F. M., Bridges, E., Interiano, R. B., Qu, C., Vogt, N., Li, J.-L., Baban, D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422015112 · Cited by 138
Self-citationHyde, R., Cwiklinski, E. L., MacAulay, K., Taylor, P. M., & Hundal, H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611520200 · Cited by 132
Woo, Y. M., Shin, Y., Lee, E. J., Lee, S., Jeong, S. H., Kong, H. K., Park, E. Y., Kim, H. K., Han, J., Chang, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132285 · Cited by 124
Generali, D., Buffa, F. M., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.7083 · Cited by 116
Self-citationMiller, T. W., Balko, J. M., Ghazoui, Z. F., Dunbier, A. K., Anderson, H., Dowsett, M., Gonzalez-Angulo, A. M., Mills, G. B., Miller, W. R., Wu, H., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2567 · Cited by 115
Gaccioliy, F., Huang, C. C., Wang, C., Bevilacqua, E., Franchi-Gazzola, R., Gazzola, G. C., Bussolati, O., Snider, M. D., & Hatzoglou, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600341200 · Cited by 112
Apical Transporters for Neutral Amino Acids: Physiology and Pathophysiology
Bröer, S. (2008) · Physiology · doi:10.1152/physiol.00045.2007 · Cited by 107
Bröer, A., Gauthier-Coles, G., Rahimi, F., van Geldermalsen, M., Dorsch, D., Wegener, A., Holst, J., & Bröer, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006378 · Cited by 101
MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
Craze, M. L., Cheung, H., Jewa, N., Coimbra, N. D. M., Soria, D., Ansari, R. E., Aleskandarany, M. A., Cheng, K. W., Diez, M., Nolan, C. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.387 · Cited by 100
Shajahan‐Haq, A. N., Cook, K. L., Schwartz‐Roberts, J. L., Eltayeb, A. E., Demas, D. M., Wärri, A. M., Facey, C. O. B., Hilakivi-Clarke, L. A., & Clarke, R. C. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-239 · Cited by 94
SNAT2 transceptor signalling via mTOR A role in cell growth and proliferation
Hundal, H. S. (2011) · Frontiers in Bioscience · doi:10.2741/e332 · Cited by 91
Gene expression and hypoxia in breast cancer
Favaro, E., Lord, S., Harris, A. L., & Buffa, F. M. (2011) · Genome Medicine · doi:10.1186/gm271 · Cited by 88
Self-citationChen, Z., Wang, Y., Warden, C., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.02.004 · Cited by 82
Hypoxia-inducible factors enhance glutamate signaling in cancer cells
Hu, H., Takano, N., Xiang, L., Gilkes, D. M., Luo, W., & Semenza, G. L. (2014) · Oncotarget · doi:10.18632/oncotarget.2593 · Cited by 75
Fan, S.-J., Snell, C., Turley, H., Li, J.-L., McCormick, R., Perera, S. M. W., Heublein, S., Kazi, S., Azad, A., Wilson, C., et al. (2016) · Oncogene · doi:10.1038/onc.2015.363 · Cited by 65
Self-citationUno, K., Yamada, T., Ishigaki, Y., Imai, J., Hasegawa, Y., Sawada, S., Kaneko, K., Ono, H., Asano, T., Oka, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms8940 · Cited by 65
Timosenko, E., Ghadbane, H., Silk, J. D., Shepherd, D., Gileadi, U., Howson, L. J., Laynes, R., Zhao, Q., Strausberg, R. L., Olsen, L. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3502 · Cited by 64
Self-citationCho, J., Kim, D., Lee, S., & Lee, Y. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0162 · Cited by 64
Ulaner, G. A., Goldman, D. A., Corben, A. D., Lyashchenko, S. K., Gönen, M., Lewis, J. S., & Dickler, M. N. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183335 · Cited by 63
Ansari, R. E., Craze, M. L., Diez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0038-5 · Cited by 62
Hatanaka, T., Hatanaka, Y., Tsuchida, J., Ganapathy, V., & Setou, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604534200 · Cited by 58
Leiblich, A., Marsden, L., Gandy, C., Corrigan, L., Jenkins, R., Hamdy, F., & Wilson, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214517109 · Cited by 54
Nardi, F., Hoffmann, T. M., Stretton, C., Cwiklinski, E., Taylor, P. M., & Hundal, H. S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.625137 · Cited by 42
Jia, X., Qi, H., Li, L., Li, D., Li, J., Mo, M., Wang, Y., Shao, Z., Shen, Z., Cheng, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3257 · Cited by 40
Krokowski, D., Guan, B., Wu, J., Zheng, Y., Pattabiraman, P. P., Jobava, R., Gao, X., Di, X.-J., Snider, M. D., Mu, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.027 · Cited by 37
Oh, R. S., Pan, W., Yalçın, A., Zhang, H., Guilarte, T. R., Hotamışlıgil, G. S., Christiani, D. C., & Lu, Q. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311217 · Cited by 36
Estrogen and hypoxia regulate estrogen receptor alpha in a synergistic manner
Yi, J. M., Kwon, H. Y., Cho, J. Y., & Lee, Y. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.142 · Cited by 31
Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells
Padró, M., Louie, R. J., Lananna, B. V., Krieg, A. J., Timmerman, L., & Chan, D. A. (2017) · BMC Cancer · doi:10.1186/s12885-017-3140-9 · Cited by 28
Bhat, H., & Vadgama, J. V. (2002) · International Journal of Molecular Medicine · doi:10.3892/ijmm.9.3.271 · Cited by 22
Velázquez‐Villegas, L. A., Ortíz-Ortega, V. M., Ström, A., Torres, N., Engler, D. A., Matsunami, R. K., Ordaz‐Rosado, D., García-Becerra, R., López‐Barradas, A. M., Larrea, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412099111 · Cited by 21
SNAT2 transceptor signalling via mTOR: A role in cell growth and proliferation?
Pinilla, J. (2009) · Frontiers in Bioscience-Elite · doi:10.2741/332 · Cited by 19
Cited by
Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654
“Importantly, both the glutamine transporters and glutaminase are upregulated in tumor cells through oncogene activation or hypoxia (Bott et al., 2015; Lukey et al., 2016; Morotti et al., 2019).”
BackgroundCellular Adaptation to Hypoxia through Hypoxia Inducible Factors and beyond
Lee, P., Chandel, N. S., & Simon, M. C. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0227-y · Cited by 1,272
Glutamine reliance in cell metabolism
Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
The effect of HIF on metabolism and immunity
Taylor, C. T., & Scholz, C. C. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00587-8 · Cited by 517
Metadata
- Authors
- Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., Teoh, E. J., Cheng, W.-C., Lord, S., Anastasiou, D., Haider, S., McIntyre, A., Goberdhan, D. C. I., Buffa, F., & Harris, A. L.
- Affiliations
- Cancer Research UK (GB)
- King Abdulaziz University (SA)
- John Radcliffe Hospital (GB)
- The Francis Crick Institute (GB)
- University of Oxford (GB)
- Institute of Cancer Research (GB)
- University of Nottingham (GB)
- University of California San Diego (US)
- Corresponding author
- Morotti, Matteo
- Harris, Adrian L.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-05-31
- Volume
- 116
- Issue
- 25
- Pages
- 12452-12461
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6589752
- OpenAlex
- W2885171918
- Cited by
- 131
- References
- 83
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 24 · 2023: 14 · 2022: 17 · 2021: 27 · 2020: 20 · 2019: 2
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by-nc-nd)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Archivio istituzionale della Ricerca - Bocconi (submittedVersion)
- The Francis Crick Institute
- Funders
- Breast Cancer Research Foundation (BCRF-17-064)
- Fondazione Umberto Veronesi (2018)
- Cancer Research UK (ANR00163)
- Oxford NIHR Biomedical Research Centre (2018)
- Oxfordshire Community Foundation (8297)
- Friends of Kennington Cancer Fund (2018)
- RCUK | Medical Research Council (MC_UP_1202/1)
- Francis Crick Institute (FC001033)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- SNAT2, SLC38A2, breast cancer, hypoxia, endocrine therapy resistance, estrogen receptor alpha, HIF-1α, glutamine transport, fulvestrant, antiestrogen therapy, anti-VEGF therapy, tumor hypoxia, drug resistance
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Cell Hypoxia, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Estrogen Receptor Modulators, Amino Acid Transport System A, Cell Line, Tumor, Estrogen Receptor alpha, Mice, Tumor Microenvironment, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.